Combining rituximab with mycophenolate for the treatment of interstitial lung disease

Eur Respir J. 2023 Jun 8;61(6):2300614. doi: 10.1183/13993003.00614-2023. Print 2023 Jun.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Double-Blind Method
  • Enzyme Inhibitors
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Interstitial* / drug therapy
  • Mycophenolic Acid* / therapeutic use
  • Rituximab / therapeutic use

Substances

  • Rituximab
  • Mycophenolic Acid
  • Immunosuppressive Agents
  • Enzyme Inhibitors